1. Bristol-Myers Squibb. Opdivo: summary of product characteristics [October 29, 2021]. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf.
2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
3. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial;Motzer;Cancer,2020
4. Partial nephrectomy versus radical nephrectomy for large (≥7 cm) renal tumors: a systematic review and meta-analysis;Deng;Urol Oncol,2019
5. Ljungberg B, Albiges L, Bensalah K, et al. EAU guideline: renal cell carcinoma. Arnhem, The Netherlands: European Association of Urology; 2020. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Renal-Cell-Carcinoma-2020.pdf.